We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

185 hedge funds and large institutions have $2.93B invested in Amicus Therapeutics in 2017 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 77 increasing their positions, 56 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 56

29% more funds holding in top 10

Funds holding in top 10: 79 (+2)

18% more call options, than puts

Call options by funds: $95.2M | Put options by funds: $80.6M

3.21% more ownership

Funds ownership: 120.55%123.77% (+3.2%)

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

1% less funds holding

Funds holding: 186185 (-1)

2% less capital invested

Capital invested by funds: $2.99B → $2.93B (-$56M)

Holders
185
Holders Change
-1
Holders Change %
-0.54%
% of All Funds
4.2%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.2%
New
26
Increased
77
Reduced
56
Closed
26
Calls
$95.2M
Puts
$80.6M
Net Calls
+$14.7M
Net Calls Change
+$8.28M
Name Holding Trade Value Shares
Change
Change in
Stake
Balyasny Asset Management
201
Balyasny Asset Management
Illinois
-$195K -12,900 Closed
QSS
202
Quantitative Systematic Strategies
Florida
-$168K -11,117 Closed
Creative Planning
203
Creative Planning
Kansas
-$156K -10,343 Closed
EGM
204
Engineers Gate Manager
New York
-$155K -10,300 Closed
NFG
205
Next Financial Group
Texas
-$38K -2,625 Closed
IA
206
IFP Advisors
Florida
-$16.5K -1,200 -98%
FANJ
207
Financial Architects (New Jersey)
New Jersey
-$14K -900 Closed
Acadian Asset Management
208
Acadian Asset Management
Massachusetts
-$7K -446 Closed
MAM
209
Meeder Asset Management
Ohio
-$4K -271 Closed

FOLD Hedge Fund Activity: Q4 2017 in Review

185 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2017, worth a combined $2.93B — down 1.9% from $2.99B a quarter earlier.

Fund positioning in FOLD was balanced in Q4 2017: 26 funds opened new positions, 26 closed out, 77 added to existing stakes and 56 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $76.6M. The largest seller was Farallon Capital Management, cutting an estimated $31.6M.

  • 185 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2017, down from 186 in Q3 2017.
  • Funds reported $2.93B of Amicus Therapeutics stock for Q4 2017, down 1.9% quarter-over-quarter.
  • 26 funds opened new Amicus Therapeutics positions in Q4 2017 and 26 closed out, a net change of 0 holders.
  • The largest Amicus Therapeutics buyer in Q4 2017 was OrbiMed, an estimated $76.6M added.
  • The largest Amicus Therapeutics seller in Q4 2017 was Farallon Capital Management, an estimated $31.6M sold.

Based on aggregated 13F filings for Q4 2017.